Christopher Hulton, PhD

Senior Scientist, Drug Discovery Biology, Treeline Biosciences, Cambridge, MA

Christopher Hulton, PhD

Senior Scientist, Drug Discovery Biology, Treeline Biosciences, Cambridge, MA
Share
Share
Pictured: Christopher Hulton

End Year

2019

Education

BS, Northeastern University

Current Title & Affiliations

Research Scientist, C4 Therapeutics Inc.

Publications

Wohlhieter CA, Richards AL, Uddin F, Hulton CH, Quintanal-Villalonga À, Martin A, de Stanchina E, Bhanot U, Asher M, Shah NS, Hayatt O, Buonocore DJ, Rekhtman N, Shen R, Arbour KC, Donoghue M, Poirier JT, Sen T, Rudin CM. (2020) Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. Cell Rep.

Hulton, C.H., Costa, E.A., Shah, N.S. et al. Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics. (2020) Nat Cancer 1, 359–369 (2020). doi.org/10.1038/s43018-020-0040-8

View a full listing of Christopher Hulton’s journal articles.